Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.

Piulats JM, Vidal A, García-Rodríguez FJ, Muñoz C, Nadal M, Moutinho C, Martínez-Iniesta M, Mora J, Figueras A, Guinó E, Padullés L, Aytés À, Molleví DG, Puertas S, Martínez-Fernández C, Castillo W, Juliachs M, Moreno V, Muñoz P, Stefanovic M, Pujana MA, Condom E, Esteller M, Germà JR, Capella G, Farré L, Morales A, Viñals F, García-Del-Muro X, Cerón J, Villanueva A.

Clin Cancer Res. 2018 Aug 1;24(15):3755-3766. doi: 10.1158/1078-0432.CCR-17-1898. Epub 2018 Apr 4.

2.

Managing cancer care through service delivery networks: The role of professional collaboration in two European cancer networks.

Prades J, Morando V, Tozzi VD, Verhoeven D, Germà JR, Borras JM.

Health Serv Manage Res. 2018 Aug;31(3):120-129. doi: 10.1177/0951484817745219. Epub 2017 Dec 14.

PMID:
29239683
3.

Radium-223 international early access program: results from the Spanish subset.

Carles J, Méndez MJ, Pinto Á, Sáez MI, Arranz JA, Maroto P, López-Criado P, Mellado B, Donas JG, Hernando S, León L, Del Alba AG, Laínez N, Esteban E, Reynés G, Pérez-Gracia JL, Germà JR, López-Brea M, Pérez-Valderrama B, Moretones C, Castellano D.

Future Oncol. 2018 Jan;14(1):41-50. doi: 10.2217/fon-2017-0297. Epub 2017 Dec 13.

PMID:
29232987
4.

Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.

Clopes A, Gasol M, Cajal R, Segú L, Crespo R, Mora R, Simon S, Cordero LA, Calle C, Gilabert A, Germà JR.

J Med Econ. 2017 Jan;20(1):1-7. Epub 2016 Aug 3.

PMID:
27441909
5.

Re: Mette Saksø Mortensen, Jakob Lauritsen, Maria Gry Gundgaard, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 2014;66:1172-8.

Aparicio J, Maroto P, Sastre J, Germà JR; Spanish Germ Cell Cancer Group.

Eur Urol. 2015 May;67(5):e93-4. doi: 10.1016/j.eururo.2014.11.041. Epub 2014 Dec 1. No abstract available.

PMID:
25477259
6.

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

Aparicio J, Maroto P, García del Muro X, Sánchez-Muñoz A, Gumà J, Margelí M, Sáenz A, Sagastibelza N, Castellano D, Arranz JA, Hervás D, Bastús R, Fernández-Aramburo A, Sastre J, Terrasa J, López-Brea M, Dorca J, Almenar D, Carles J, Hernández A, Germà JR.

Ann Oncol. 2014 Nov;25(11):2173-8. doi: 10.1093/annonc/mdu437. Epub 2014 Sep 10.

7.

Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.

Castellano D, Antón Aparicio LM, Esteban E, Sánchez-Hernández A, Germà JR, Batista N, Maroto P, Pérez-Valderrama B, Luque R, Méndez-Vidal MJ; cabazitaxel EAP study.

Expert Opin Drug Saf. 2014 Sep;13(9):1165-73. doi: 10.1517/14740338.2014.939583. Epub 2014 Jul 7.

PMID:
25001524
8.

The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.

Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Clin Cancer Res. 2014 Feb 1;20(3):658-67. doi: 10.1158/1078-0432.CCR-13-1131. Epub 2013 Nov 25.

9.

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.

Juliachs M, Vidal A, Del Muro XG, Piulats JM, Condom E, Casanovas O, Graupera M, Germà JR, Villanueva A, Viñals F.

BMC Cancer. 2013 Aug 10;13:382. doi: 10.1186/1471-2407-13-382.

10.

The impact of KRAS mutations on VEGF-A production and tumour vascular network.

Figueras A, Arbos MA, Quiles MT, Viñals F, Germà JR, Capellà G.

BMC Cancer. 2013 Mar 18;13:125. doi: 10.1186/1471-2407-13-125.

11.

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.

Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Int J Cancer. 2013 Jul;133(1):235-46. doi: 10.1002/ijc.28009. Epub 2013 Feb 12.

12.

A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germá JR, O'Bryan-Tear CG, Haider T, Hoskin P.

Eur Urol. 2013 Feb;63(2):189-97. doi: 10.1016/j.eururo.2012.09.008. Epub 2012 Sep 13.

PMID:
23000088
13.

Clinicopathological risk factors of Stage II colon cancer: results of a prospective study.

Santos C, López-Doriga A, Navarro M, Mateo J, Biondo S, Martínez Villacampa M, Soler G, Sanjuan X, Paules MJ, Laquente B, Guinó E, Kreisler E, Frago R, Germà JR, Moreno V, Salazar R.

Colorectal Dis. 2013 Apr;15(4):414-22. doi: 10.1111/codi.12028.

PMID:
22974322
14.

Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR.

Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8.

PMID:
22772380
15.

Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study.

Aparicio J, Maroto P, del Muro XG, Gumà J, Sánchez-Muñoz A, Margelí M, Doménech M, Bastús R, Fernández A, López-Brea M, Terrassa J, Meana A, del Prado PM, Sastre J, Satrústegui JJ, Gironés R, Robert L, Germà JR.

J Clin Oncol. 2011 Dec 10;29(35):4677-81. doi: 10.1200/JCO.2011.36.0503. Epub 2011 Oct 31.

PMID:
22042940
16.

SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010).

Aparicio J, Sastre J, Germà JR, Isla D.

Clin Transl Oncol. 2011 Aug;13(8):560-4. doi: 10.1007/s12094-011-0697-7.

PMID:
21821490
17.

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.

J Natl Cancer Inst. 2010 Oct 20;102(20):1547-56. doi: 10.1093/jnci/djq362. Epub 2010 Oct 11.

18.

Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.

Marberger M, Kaisary AV, Shore ND, Karlin GS, Savulsky C, Mis R, Leuratti C, Germa JR.

Clin Ther. 2010 Apr;32(4):744-57. doi: 10.1016/j.clinthera.2010.04.013.

PMID:
20435244
19.

CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD).

Oaknin A, Barretina P, Pérez X, Jimenez L, Velasco M, Alsina M, Brunet J, Germà JR, Beltran M.

Int J Gynecol Cancer. 2010 Jan;20(1):87-91. doi: 10.1111/IGC.0b013e3181c16ba1.

PMID:
20130507
20.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; Spanish Society of Medical Oncology.

Ann Oncol. 2010 Feb;21(2):195-8. doi: 10.1093/annonc/mdp595. No abstract available.

21.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

22.

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.

Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652.

23.

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model.

Laquente B, Lacasa C, Ginestà MM, Casanovas O, Figueras A, Galán M, Ribas IG, Germà JR, Capellà G, Viñals F.

Mol Cancer Ther. 2008 Mar;7(3):638-47. doi: 10.1158/1535-7163.MCT-07-2122.

24.

The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity.

Majem M, Galán M, Pérez FJ, Muñoz M, Chicote S, Soler G, Navarro M, Martínez-Villacampa M, García del Muro X, Dotor E, Laquente B, Germà JR.

Clin Transl Oncol. 2007 Dec;9(12):784-8.

PMID:
18158982
25.

[Impact on budget of new drugs for colorectal cancer treatment].

Corral MJ, Clopès A, Navarro M, Germà JR, Borràs JM.

Med Clin (Barc). 2007 Jun 23;129(4):134-6. Spanish.

PMID:
17663967
26.

Metronomic chemotherapy: an antiangiogenic scheduling.

Laquente B, Viñals F, Germà JR.

Clin Transl Oncol. 2007 Feb;9(2):93-8. Review.

PMID:
17329220
27.

Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.

Molleví DG, Serrano T, Ginestà MM, Valls J, Torras J, Navarro M, Ramos E, Germà JR, Jaurrieta E, Moreno V, Figueras J, Capellà G, Villanueva A.

Carcinogenesis. 2007 Jun;28(6):1241-6. Epub 2007 Jan 27.

PMID:
17259658
28.

Treatment of stage I testicular germ-cell tumors.

Aparicio J, Germà JR.

Med Oncol. 2006;23(3):305-15. Review.

PMID:
17018887
29.

Myths and facts on adjuvant carboplatin for stage I seminoma.

Aparicio J, Germà JR.

J Clin Oncol. 2006 Jul 20;24(21):e40. No abstract available.

PMID:
16849740
30.

Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.

Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, Capellá G, Villanueva A.

J Clin Oncol. 2006 Apr 1;24(10):1603-11.

PMID:
16575011
31.

Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.

Majem M, Cascallo M, Bayo-Puxan N, Mesia R, Germa JR, Alemany R.

Cancer Gene Ther. 2006 Jul;13(7):696-705. Epub 2006 Feb 24.

PMID:
16498429
32.

Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

Aparicio J, Germà JR, García del Muro X, Maroto P, Arranz JA, Sáenz A, Barnadas A, Dorca J, Gumà J, Olmos D, Bastús R, Carles J, Almenar D, Sánchez M, Paz-Ares L, Satrústegui JJ, Mellado B, Balil A, López-Brea M, Sánchez A; Second Spanish Germ Cell Cancer Cooperative Group.

J Clin Oncol. 2005 Dec 1;23(34):8717-23. Epub 2005 Oct 31.

PMID:
16260698
33.

Founder mutation in familial adenomatous polyposis (FAP) in the Balearic Islands.

González S, Blanco I, Campos O, Julià M, Reyes J, Llompart A, Cabeza E, Germà JR, Obrador A, Capellá G.

Cancer Genet Cytogenet. 2005 Apr 1;158(1):70-4.

PMID:
15771908
34.

p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.

Garcia del Muro X, Condom E, Vigués F, Castellsagué X, Figueras A, Muñoz J, Solá J, Soler T, Capellà G, Germà JR.

Cancer. 2004 May 1;100(9):1859-67.

35.

Cancer care in rural areas.

Colomer R, Germà JR, Rosell R, Borràs JM.

Br J Cancer. 2004 Apr 19;90(8):1688; author reply 1689. No abstract available.

36.

Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer.

Urruticoechea A, Mesía R, Domínguez J, Falo C, Escalante E, Montes A, Sancho C, Cardenal F, Majem M, Germà JR.

Lung Cancer. 2004 Feb;43(2):209-14.

PMID:
14739042
37.

Common genetic evolutionary pathways in familial adenomatous polyposis tumors.

Tarafa G, Prat E, Risques RA, González S, Camps J, Grau M, Guinó E, Moreno V, Esteller M, Herman JG, Germà JR, Miró R, Peinado MA, Capellá G.

Cancer Res. 2003 Sep 15;63(18):5731-7.

38.

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.

Aparicio J, García del Muro X, Maroto P, Paz-Ares L, Alba E, Sáenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sánchez M, Fernández A, Sastre J, Carles J, Dorca J, Gumà J, Yuste AL, Germà JR; Spanish Germ Cell Cancer Cooperative Group (GG).

Ann Oncol. 2003 Jun;14(6):867-72.

39.

[Metastatic cáncer presentation. Validation of a diagnostic algorithm with 221 consecutive patients].

Losa Gaspà F, Germá JR, Albareda JM, Fernández-Ortega A, Sanjosé S, Fernández Trigo V.

Rev Clin Esp. 2002 Jun;202(6):313-9. Spanish.

PMID:
12093395
40.

Mismatch repair gene analysis in Catalonian families with colorectal cancer.

Palicio M, Balmaña J, González S, Blanco I, Marcuello E, Peinado MA, Julià G, Germà JR, López López JJ, Brunet J, Capellà G.

J Med Genet. 2002 Jun;39(6):E29. No abstract available.

41.

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.

Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, Parra MS, Tisaire JL, Maroto P, Germá JR.

Br J Cancer. 2002 Feb 1;86(3):326-30.

42.

[Clinical pattern and therapeutic results obtained in Germ-Cell testicular cancer in Spain based on a consecutive series of 1250 patients].

Germà JR, García Del Muro X, Maroto P, Lianes P, Arranz JA, Gumà J, Aparicio J, Sastre J, Alba E, Terrasa J, Sáenz A, Fernández A; Grupo Germinal.

Med Clin (Barc). 2001 Apr 7;116(13):481-6. Spanish.

PMID:
11412604
43.

Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.

Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JL, Espinas JA, Germa JR.

BMJ. 2001 Apr 7;322(7290):826.

44.

K-ras and p16 aberrations confer poor prognosis in human colorectal cancer.

Esteller M, González S, Risques RA, Marcuello E, Mangues R, Germà JR, Herman JG, Capellà G, Peinado MA.

J Clin Oncol. 2001 Jan 15;19(2):299-304.

PMID:
11208819
45.

Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer.

Garcia del Muro X, Torregrosa A, Muñoz J, Castellsagué X, Condom E, Vigués F, Arance A, Fabra A, Germà JR.

Eur J Cancer. 2000 Feb;36(3):357-62.

PMID:
10708937
46.

Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effect on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation.

Cancelas JA, Querol S, Canals C, Picón M, Azqueta C, Solà C, Montes A, Amill B, Griera E, Inglés J, López JJ, Germà JR, García-López J.

Transfusion. 1998 Nov-Dec;38(11-12):1063-70.

PMID:
9838939
47.

Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis.

Garcia-del-Muro X, Vadell C, Pérez Manga G, Bover I, Rifá J, Beltrán M, Barros MM, Germá JR, Fabregat X, Moreno V, Salvador A, Viladiu P.

Eur J Cancer. 1998 Jan;34(1):193-5.

PMID:
9624257
48.

CDC group IV c-2 infection in a stem cell transplant recipient.

Arance A, Montes A, Cisnal M, Mesía R, Falo C, García del Muro J, Germà JR.

Bone Marrow Transplant. 1997 Dec;20(11):1005-6.

49.

[Primary germ cell tumors of the central nervous system].

Losa F, García del Muro J, Germà JR.

Neurologia. 1997 Jun-Jul;12(6):249-54. Review. Spanish.

PMID:
9303592
50.

Mortality in testicular cancer: 10 years' experience at a single centre.

Germa JR, Mercedes A, Tabernero JM, Palou J, Algaba F, Villavicencio H, Sole FJ.

Urol Int. 1996;57(1):32-7.

PMID:
8840488

Supplemental Content

Loading ...
Support Center